Abstract

BackgroundSeveral new drugs, including ustekinumab, apremilast, and secukinumab, became available for the treatment of psoriatic arthritis (PsA) over the last years, broadening our possibilities to treat the disease effectively. The...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.
Arno W R Van Kuijk ... Leonieke J J Van Mens
Rheumatology (Oxford, England) | VOL. 57
Arno W R Van Kuijk, et. al.Arno W R Van Kuijk ... Leonieke J J Van Mens
24 May 2017
Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound.
Josef Hermann ... Christina Duftner
Rheumatology (Oxford, England) | VOL. 58
Josef Hermann, et. al.Josef Hermann ... Christina Duftner
14 Jun 2019
What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?
Umut Kalyoncu ... Sibel Zehra Aydin
Clinical and Experimental Rheumatology | VOL. 37
Umut Kalyoncu, et. al.Umut Kalyoncu ... Sibel Zehra Aydin
11 Feb 2019
P173 Evaluating disease activity in established psoriatic arthritis with ultrasound
Philomena Gallagher ... Douglas J Veale
Rheumatology | VOL. 62
Philomena Gallagher, et. al.Philomena Gallagher ... Douglas J Veale
24 Apr 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers